Live from the NIH registry
Studies recruiting near Muskegon right now
Top 25 of 65 recruiting studies, sorted by proximity — each links to its official registry page
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 2, Phase 3
Interventional 189 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 1,524 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
N/A
Observational 5,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute LAO
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Urothelial Carcinoma
Phase 2
Interventional 372 participants sought
The Cancer & Hematology Centers — Norton Shores, Michigan (4.1 mi)
· Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Phase 2
Interventional 46 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 3
Interventional 94 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Mesothelioma, Non Small Cell Lung Cancer
Phase 1
Interventional 336 participants sought
Cancer and Hematology Centers of Western Michigan — Norton Shores, Michigan (4.1 mi)
· Sponsor: Bristol-Myers Squibb
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Lung Non-Small Cell Carcinoma
Phase 2
Interventional 88 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Phase 3
Interventional 486 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 247 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Project: Every Child for Younger Patients With Cancer
Adrenal Gland Pheochromocytoma, Carcinoma In Situ
N/A
Observational 75,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Children's Oncology Group
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 2
Interventional 81 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
N/A
Observational 2,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Refractory Differentiated Thyroid Gland Carcinoma
Phase 3
Interventional 264 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
N/A
Interventional 535 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Phase 3
Interventional 303 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Phase 2
Interventional 461 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Phase 3
Interventional 255 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
N/A
Interventional 1,956 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Pancreatic Neoplasm
N/A
Observational 770 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group